Abstract:
Melanoma has emerged as a paradigm for modern cancer therapy, demonstrating how molecularly targeted treatments and immunotherapy can transform outcomes in advanced malignancy. Despite these advances, therapeutic resistance, tumor heterogeneity, immune evasion, and disease recurrence remain major barriers to achieving durable clinical responses. The next generation of melanoma therapy is therefore moving beyond single-target approaches toward integrated strategies that simultaneously address tumor evolution, immune dysfunction, and the tumor microenvironment.
This presentation will highlight emerging therapeutic approaches that are reshaping the melanoma treatment landscape. Particular emphasis will be placed on next-generation immune checkpoint strategies, personalized immunotherapy, adoptive cellular therapies, tumor-infiltrating lymphocyte therapy, neoantigen-based vaccines, bispecific antibodies, and novel approaches for enhancing antitumor T-cell activity. Recent advances in neoadjuvant immunotherapy are also changing the therapeutic paradigm by enabling treatment to be delivered at a stage when tumor burden and immune suppression may be more effectively controlled.
The presentation will further explore precision targeting of melanoma-associated molecular alterations, including MAPK and PI3K/AKT/mTOR signaling, and the emerging concept of combining targeted therapy with immunotherapy to overcome adaptive resistance. Increasing evidence indicates that therapeutic failure is driven not only by genetic alterations within melanoma cells but also by dynamic interactions with immune cells, stromal components, metabolic pathways, and the tumor microenvironment. Consequently, targeting cancer stemness, immune-suppressive myeloid populations, angiogenesis, tumor metabolism, and mechanisms of immune exhaustion represents an important frontier in melanoma therapy.
Personalized treatment approaches based on tumor genomics, immune profiling, circulating tumor DNA, tumor mutational burden, and neoantigen landscapes are expected to further refine patient selection and therapeutic decision-making. Emerging personalized neoantigen vaccines and autologous neoantigen-specific T-cell therapies illustrate the potential of highly individualized treatment strategies.
Overall, the future of melanoma therapy lies in developing rational, biomarker-driven combinations capable of overcoming tumor plasticity and immune resistance while minimizing treatment-associated toxicity. Integrating precision medicine, immunotherapy, cellular therapy, molecular targeting, and tumor microenvironment-directed interventions may ultimately transform melanoma from a highly aggressive malignancy into a more effectively controllable and potentially curable disease.
